<DOC>
	<DOCNO>NCT01207323</DOCNO>
	<brief_summary>This Phase I , multicenter , open-label study MEHD7945A patient incurable , locally advanced , metastatic epithelial malignancy progress despite standard therapy standard therapy exist .</brief_summary>
	<brief_title>A Study Safety Pharmacokinetics MEHD7945A Patients With Locally Advanced Metastatic Epithelial Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms , Glandular Epithelial</mesh_term>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Immunoglobulin G</mesh_term>
	<criteria>Life expectancy &gt; /= 12 week Availability willingness provide sufficient tumor tissue sample test Doseescalation stage : Patients histologically document incurable , locally advanced , metastatic epithelial malignancy progress despite standard therapy standard therapy exist Expansion stage : Patients one follow epithelial , histologicallydocumented , incurable , locally advanced , metastatic tumor progress despite standard therapy standard therapy exist : colorectal cancer , nonsmall cell lung cancer , head neck squamous cell carcinoma , pancreatic cancer Use effective mean contraception ( e.g. , abstinence , hormonal double barrier method , surgically sterilized partner ) men woman childbearing potential enrol study &lt; 4 week since last antitumor therapy prior Day 1 study treatment Major surgical procedure within 4 week prior Day 1 study treatment Leptomeningeal disease manifestation current malignancy Active infection require IV antibiotic Active autoimmune disease control nonsteroidal antiinflammatory drug Symptomatic hypercalcemia require continue use bisphosphonate therapy Current severe , uncontrolled systemic disease History cardiac heart failure New York Heart Association criterion serious cardiac arrhythmia require treatment History myocardial infarction within 6 month Day 1 , history unstable angina Clinically significant history liver disease , include viral hepatitis , current alcohol abuse , cirrhosis History interstitial lung disease History severe allergic hypersensitivity reaction therapeutic antibody require discontinuation therapy Known human immunodeficiency virus ( HIV ) infection Primary central nervous system ( CNS ) malignancy untreated/active CNS metastases Significant traumatic injury within 4 week prior Day 1 study treatment Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>